NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

不寧腿症候群市場:2020∼2026年

Restless Legs Syndrome Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 970812
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
不寧腿症候群市場:2020∼2026年 Restless Legs Syndrome Market 2020-2026
出版日期: 2020年10月19日內容資訊: 英文
簡介

全球不寧腿症候群的市場規模,在預測期間內預計以6.2%的年複合成長率擴大。不寧腿症候群(RLS)的盛行率增加,是造成市場成長的重要的要素。 RLS,由於糖尿病,帕金森氏症,腎功能衰竭,腎臟疾病等慢性疾病原因而發生。因此,這些疾病高的盛行率,創造RLS治療設備的需求,預計促進該市場的成長。

Pfizer,Inc.,GlaxoSmithKline plc,Boehringer Ingelheim GmbH,Teva Pharmaceutical Industries Ltd.,Mylan NV,Glenmark Pharmaceuticals Ltd.等,是在全球不寧腿症候群市場活動的主要企業。新產品的銷售與產品開發,是這些主要的市場參與者的中心主題。還有加上不寧腿症候群市場主要參與者,為了擴大了市場佔有率積極地採用有機或無機的市場活動。

本報告提供全球不寧腿症候群市場相關調查,市場概要,以及各類型,各治療法,各終端用戶,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 規則與法規

第3章 競爭情形

  • 企業佔有率分析
  • 重要的策略分析
  • 主要企業分析
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries, Ltd.
    • UCB SA

第4章 市場決策要素

  • 動機
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 全球不寧腿症候群市場:各治療法
    • 投藥
    • 治療
    • 設備
  • 全球不寧腿症候群市場:各終端用戶
    • 醫院
    • 居家醫療
    • 其他

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他

第7章 企業簡介

  • Akorn, Inc.
  • Arbor Pharmaceuticals, LLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals plc
  • Kyowa Hakko Kirin Co. Ltd.
  • LGM Pharma
  • Mallinckrodt Pharmaceuticals
  • Merck Co, Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Serina Therapeutics, Inc.
  • Teva Pharmaceutical Industries, Ltd.
  • UCB S.A.
目錄
Product Code: OMR2022577

Global Restless Legs Syndrome Market Size, Share & Trends Analysis Report by Type (Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome), by Treatment (Medication, Therapy, Devices), by End-User (Hospitals, Homecare, Others) Forecast Period 2020-2026

The global restless legs syndrome market is projected to grow at a CAGR of 6.2% during the forecast period. The increase in the prevalence of restless legs syndrome is a key factor responsible for the growth of the market. RLS occurs due to chronic diseases such as diabetes, Parkinson's disease, kidney failure, or renal diseases. Therefore, the high prevalence of the diseases is anticipated to create the demand for devices for the treatment of RLS which in turn will drive the market growth.

The restless leg syndrome market is segmented based on type, treatment, and end-users. Based on type the market is sub-segmented into primary restless legs syndrome, secondary restless legs syndrome. Based on treatment, the market is segmented into Medication, Therapy, Devices. Based on end-user, the market is segmented into hospitals, home care, and others. Hospital is forecast to be the considerable segment in the end-user market owing to the higher lifecycle, better efficiency of the medical equipment in the hospitals.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the major share in the Restless Leg Syndrome market due to the higher awareness among the patients related to the available treatments for the treatment of restless legs syndrome. Further, the advanced healthcare system in the country has supported the growth of the devices and therapies that are used in the treatment of the restless legs syndrome. Asia-Pacific is anticipated to hold considerable market share during the forecast period.

Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals Ltd., and so on are the key players operating in the global restless legs syndrome market. The new product launch and product development are the core focus of these major market players. Moreover, the key players of the Restless Leg Syndrome market are actively adopting organic or inorganic market activities to increase their market share.

Research Methodology

The market study of the global restless leg syndrome market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report is intended for healthcare companies, hospitals, clinics, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Restless Leg Syndrome Market Research and Analysis by Treatment

2. Global Restless Leg Syndrome Market Research and Analysis by End-User

The Report Covers:

Comprehensive research methodology of the global restless leg syndrome market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global restless leg syndrome market.

Insights about market determinants which are stimulating the global restless leg syndrome market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. GlaxoSmithKline plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Boehringer Ingelheim GmbH
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Teva Pharmaceutical Industries, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. UCB SA
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Restless Leg SyndromeMarket by Treatment
    • 5.1.1. Medication
    • 5.1.2. Therapy
    • 5.1.3. Devices
  • 5.2. Global Restless Legs Syndrome Market by End-User
    • 5.2.1. Hospitals
    • 5.2.2. Homecare
    • 5.2.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Akorn, Inc.
  • 7.2. Arbor Pharmaceuticals, LLC
  • 7.3. Boehringer Ingelheim GmbH
  • 7.4. GlaxoSmithKline plc
  • 7.5. Glenmark Pharmaceuticals Ltd.
  • 7.6. Jazz Pharmaceuticals plc
  • 7.7. Kyowa Hakko Kirin Co. Ltd.
  • 7.8. LGM Pharma
  • 7.9. Mallinckrodt Pharmaceuticals
  • 7.10. Merck Co, Inc.
  • 7.11. Mylan N.V.
  • 7.12. Pfizer, Inc.
  • 7.13. Serina Therapeutics, Inc.
  • 7.14. Teva Pharmaceutical Industries, Ltd.
  • 7.15. UCB S.A.

LIST OF TABLES

  • 1. GLOBAL RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 2. GLOBAL RESTLESS LEGS SYNDROME MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL RESTLESS LEGS SYNDROME THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL RESTLESS LEGS SYNDROME DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 6. GLOBAL HOSPITALS FOR RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL HOMECARES FOR RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 10. NORTH AMERICAN RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICANRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 13. EUROPEAN RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. EUROPEANRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. EUROPEANRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 16. ASIA-PACIFIC RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFICRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 19. REST OF THE WORLDRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLDRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RESTLESS LEGS SYNDROME MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 2. GLOBAL RESTLESS LEGS SYNDROME MARKET SHARE BY END-USER, 2019 VS 2026 (%)
  • 3. GLOBAL RESTLESS LEGS SYNDROME MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. THE US RESTLESS LEG SYNDROME MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA RESTLESS LEG SYNDROME MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)